|
Post by JHam on Nov 20, 2014 17:27:46 GMT
Now 13.89% and 9.39%. Oh well...not complaining.
|
|
|
Post by RLC on Nov 20, 2014 17:40:43 GMT
Now 13.89% and 9.39%. Oh well...not complaining. I know it's a bummer. Hopefully volume continues picking up speed on NRIFF and it starts to trade in a closer correlation to NRI. NRIFF already at 4x the average volume today (from last 10 days trading).
|
|
|
Post by RLC on Nov 20, 2014 17:45:49 GMT
A 15,000 share order went through today @ 9:57 for $7.11/share.
|
|
|
Post by JHam on Dec 1, 2014 12:38:27 GMT
That was a "nice" dip there Friday on anemic volume. Would like to add more at these levels if I get the chance. A 15% drop when only 2,000 shares trade gets me thinking about how fast and dramatically this could move up on positive WF10 trial data.
|
|
|
Post by RLC on Dec 1, 2014 16:04:39 GMT
That was a "nice" dip there Friday on anemic volume. Would like to add more at these levels if I get the chance. A 15% drop when only 2,000 shares trade gets me thinking about how fast and dramatically this could move up on positive WF10 trial data. No kidding! I put a buy order in at $5.40 and am hoping it fills. I might just end up bumping it up to the ask price to get it filled.
|
|
|
Post by RLC on Dec 1, 2014 16:36:24 GMT
That was a "nice" dip there Friday on anemic volume. Would like to add more at these levels if I get the chance. A 15% drop when only 2,000 shares trade gets me thinking about how fast and dramatically this could move up on positive WF10 trial data. No kidding! I put a buy order in at $5.40 and am hoping it fills. I might just end up bumping it up to the ask price to get it filled. Filled at $5.41!
|
|
|
Post by JHam on Dec 1, 2014 16:50:15 GMT
No kidding! I put a buy order in at $5.40 and am hoping it fills. I might just end up bumping it up to the ask price to get it filled. Filled at $5.41! Wow, nice job!
|
|
|
Post by JHam on Dec 11, 2014 5:11:18 GMT
NRIFF dump again today. Still hoping to get some cheap shares before the end of the year. Looking to sell those ONCS trading shares if it goes back up a little bit and put them into NRIFF.
|
|
|
Post by JHam on Dec 18, 2014 19:03:45 GMT
|
|
|
Post by RLC on Dec 18, 2014 19:15:58 GMT
AWESOME!!!!! Thanks for posting this JHam! Very exciting when taking the market study they did into consideration and looking at Nuvo's market cap! I have horrible allergies and am not sufficiently helped by standard treatments so this resonates well with me. Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of immunology and topical products, today announced that 179 patients have completed its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The Company expects to release the top-line results of the study in mid-February of 2015.
"We are excited to have completed the 16-week patient treatment and monitoring phase of the study and we expect to release top-line results in mid-February 2015," said Dr. Henrich Guntermann, President, Europe & Immunology Group. "One of the main purposes of the study is to validate the results of our 60-patient Phase 2 proof-of-concept study conducted in 2010. Patients in that study and in independent case studies have reported that a single 5-day course of treatment with WF10 could provide 1 to 2 years of symptomatic relief from multiple air-borne allergens. These unique attributes make WF10 a revolutionary product candidate for patients who don't obtain adequate relief from standard allergy treatments such as antihistamines and inhaled corticosteroids."
|
|
|
Post by RLC on Dec 18, 2014 19:21:15 GMT
JHam are you planning on taking any profits here before results are announced? As of right now (considering I'm up good on this one), I'm planning on pulling 25% out sometime before we hear the results.
|
|
|
Post by RLC on Dec 18, 2014 19:51:42 GMT
I'm really surprised with the low volume both here and with TSE: NRI considering this news. Maybe people are just assuming they have plenty of time before February to load up...
|
|
|
Post by JHam on Dec 18, 2014 20:39:22 GMT
JHam are you planning on taking any profits here before results are announced? As of right now (considering I'm up good on this one), I'm planning on pulling 25% out sometime before we hear the results. No profit taking now since I am still -5% even with today's run up (remember I sold once and got back in in the $6.00s). At this point I will probably hang onto my position until it really starts to pick up steam with anticipated trial results. I probably won't have a trading position with this one. Once I am out I am all out most likely. I think that could be the mindset for a lot of people too. Since it is such a thinly traded stock on the pink sheets, people don't want to mess around and get stuck holding this one, even though there is so much upside here. We'll see how things play out, but I would never discourage anyone from taking a profit.
|
|
|
Post by JHam on Dec 22, 2014 20:28:30 GMT
|
|
|
Post by JHam on Dec 22, 2014 20:31:43 GMT
Re-iterating the excitement for upcoming data:
"We are pleased that we have been able to secure additional U.S. patent protection for WF10 in the field of allergic rhinitis," said Dr. Henrich Guntermann, Nuvo's President, Europe & Immunology Group. "We are eagerly awaiting results from our 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The patient treatment and monitoring phase of the study has now been completed and we expect to release top-line study results in mid-February of 2015."
|
|
|
Post by JHam on Dec 26, 2014 19:12:37 GMT
Added a very tiny amount today in the form of 100 shares I think I make up the entire volume of the last 3 days.
|
|
|
Post by JHam on Jan 2, 2015 17:37:50 GMT
Took BCLI profits and continued to add small increments with this one. Phase 2 WF-10 data due in February and it is still trading around cash level.
|
|
|
Post by RLC on Jan 2, 2015 18:06:02 GMT
Took BCLI profits and continued to add small increments with this one. Phase 2 WF-10 data due in February and it is still trading around cash level. I'm thinking of doing the same thing, but just have such a low cost basis with this one... I hate the idea of raising it too much. I know this is a dumb way to look at it assuming I still think there's tremendous upside potential.
|
|
|
Post by RLC on Jan 6, 2015 3:00:13 GMT
JHam, Curious what your PPS expectations are from here until mid-February. This upcoming data for WF10 seems very significant to the company. It's a 15 site Phase 2 trial, fully enrolled with 183 patients... designed to confirm efficacy found in a 2010 Phase 1 trial. If successfully brought to market, WF10 will easily be their most profitable product. Couple this with their favorable cash position, as well as their ability to continue to sell rights or license off Pennsaid 2% and I feel a PPS north of $10 is more than realistic. If there's a frenzy to get in before the data release (as you often see with Phase 2 data releases) I honestly think there's a good chance we could hit $15. That would still be a MC below $100 million. I shouldn't get ahead of myself now
|
|
|
Post by JHam on Jan 6, 2015 4:13:12 GMT
JHam, Curious what your PPS expectations are from here until mid-February. This upcoming data for WF10 seems very significant to the company. It's a 15 site Phase 2 trial, fully enrolled with 183 patients... designed to confirm efficacy found in a 2010 Phase 1 trial. If successfully brought to market, WF10 will easily be their most profitable product. Couple this with their favorable cash position, as well as their ability to continue to sell rights or license off Pennsaid 2% and I feel a PPS north of $10 is more than realistic. If there's a frenzy to get in before the data release (as you often see with Phase 2 data releases) I honestly think there's a good chance we could hit $15. That would still be a MC below $100 million. I shouldn't get ahead of myself now I was going to ask you the same question I really don't know what's going to happen, but I'll go on record saying that if the data is great and falls along the lines of interim data, which I don't see why it won't, then I would be disappointed if it does not at least double up from here. $12 is what I am hoping for, but as we just saw with BCLI, some of these unknown companies with extremely low floats can skyrocket on big news. The market for WF10 is so big that I am guilty of letting myself dream a bit with this one too, lol. I am thinking we'll start to see the volume pick up a bit and pps start to creep up as we get closer to/into February.
|
|